Can Nattokinase be added as an adjunct to hypertension treatment in a patient whose evidence‑based antihypertensive regimen is already maximized, and what dosing and monitoring are recommended?

Nattokinase as Adjunct Therapy for Maximized Hypertension Treatment

Nattokinase should NOT be added as adjunct therapy to a maximized evidence-based antihypertensive regimen, as it is not recommended in any current hypertension guidelines and lacks proven cardiovascular outcomes benefit.

Guideline-Based Approach

The 2024 ESC Guidelines for hypertension management provide a clear algorithmic approach for resistant hypertension (when BP remains uncontrolled despite maximized therapy) 1:

First-line resistant hypertension management:

• Reinforce lifestyle measures, especially sodium restriction
• Add low-dose spironolactone (25-50 mg daily)

If spironolactone ineffective or not tolerated:

• Eplerenone as alternative MRA
• Higher-dose thiazide/thiazide-like diuretic
• Loop diuretic
• Amiloride
• Beta-blocker (bisoprolol) if not already prescribed
• Alpha-blocker (doxazosin)

Third-line options:

• Centrally acting agents
• Hydralazine
• Renal denervation (only at high-volume centers after multidisciplinary assessment)

Nattokinase is conspicuously absent from these evidence-based recommendations.

Why Nattokinase Falls Short

Lack of Cardiovascular Outcomes Data

The most rigorous long-term trial directly contradicts using nattokinase for cardiovascular benefit. The 2021 Nattokinase Atherothrombotic Prevention Study enrolled 265 individuals (median age 65.3 years) and followed them for a median of 3 years 2. This study found nattokinase had zero effect on:

• Subclinical atherosclerosis progression (carotid intima-media thickness)
• Carotid arterial stiffness
• Blood pressure
• Any laboratory cardiovascular markers

This null finding in a well-designed, adequately powered trial is the highest-quality evidence available and should guide clinical decision-making when prioritizing morbidity and mortality outcomes.

Modest and Inconsistent Blood Pressure Effects

While some smaller studies show BP reductions with nattokinase, the effects are modest and clinically questionable:

• A 2023 meta-analysis found systolic BP reduction of only 3.45 mmHg and diastolic BP reduction of 2.32 mmHg 3
• An 8-week trial showed net SBP reduction of 5.55 mmHg and DBP reduction of 2.84 mmHg 4
• A 2016 North American trial showed similar modest reductions, primarily in males 5

These reductions pale in comparison to evidence-based therapies: spironolactone typically reduces BP by 15-25 mmHg systolic in resistant hypertension, with proven mortality benefit.

Concerning Lipid Effects

The 2023 meta-analysis revealed that low-dose nattokinase actually worsened lipid profiles 3:

• Increased total cholesterol (MD = 5.27 mg/dL)
• Decreased HDL cholesterol (MD = -2.76 mg/dL)
• Increased LDL cholesterol (MD = 6.49 mg/dL)
• Slight increase in blood glucose (MD = 0.40 mmol/L)

These adverse metabolic effects could potentially offset any modest BP benefit when considering overall cardiovascular risk.

Critical Clinical Pitfalls

Bleeding risk: Nattokinase has fibrinolytic activity 6, 7. Adding it to patients already on evidence-based therapy (which often includes antiplatelet agents or anticoagulants for comorbidities) creates unnecessary bleeding risk without proven benefit.

False reassurance: Prescribing nattokinase may give patients and clinicians false confidence that "something more is being done," potentially delaying implementation of truly effective interventions like renal denervation or addressing medication non-adherence.

Opportunity cost: Time and resources spent on nattokinase could be better directed toward:

• Verifying true medication adherence (pill counts, pharmacy records)
• Screening for secondary hypertension causes
• Optimizing lifestyle interventions (sodium restriction <2g/day, DASH diet, weight loss)
• Addressing white coat effect with ambulatory BP monitoring

Dosing Information (For Context Only)

Studies have used varying doses 3, 5, 4, 8:

• 2,000 FU (fibrinolytic units) daily in most BP trials
• 8,000 FU daily in cognitive studies
• 100 mg daily (standardized extract)

However, dosing is irrelevant when the intervention lacks proven clinical benefit.

The Bottom Line

When a patient's evidence-based antihypertensive regimen is truly maximized and BP remains uncontrolled, the priority is ensuring:

1. True medication adherence (not patient-reported, but verified)
2. Adequate spironolactone dosing (up to 50 mg if tolerated)
3. Optimal lifestyle measures (especially sodium <2g/day)
4. Exclusion of secondary causes (if not already done)
5. Consideration of renal denervation at appropriate centers 1

Nattokinase offers no proven mortality or morbidity benefit 2, has only modest and inconsistent BP effects 3, may worsen lipid profiles 3, and carries bleeding risk 6. It has no role in evidence-based hypertension management when guideline-recommended therapies exist.